Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Tam CS, Allan JN, Siddiqi T, Kipps TJ, et al. Blood 2022;139:3278-3289.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tam CS, Allan JN, Siddiqi T, Kipps TJ, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 2022;139:3278-3289.
PMID: 35196370